金運激光(300220.SZ)與湖畔里程簽署戰略合作框架協議 促進新業務所涉及的IP衍生品運營方向上的資源整合
格隆匯3月3日丨金運激光(300220.SZ)公佈,公司(“甲方”)與杭州湖畔里程投資管理有限公司(“湖畔里程”或“乙方”)於2020年3月2日簽署了《戰略合作框架協議》:雙方就甲方通過投資、併購潛在目標企業事宜開展戰略合作,由乙方擔任甲方的投資及併購的財務顧問及戰略合作方,達成戰略合作框架協議。
湖畔里程將從顧問及戰略合作方的角度,協助公司完成項目投資或併購等以促進公司新業務所涉及的IP衍生品運營方向上的資源整合,有利於公司戰略實施的推進及長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.